Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 481

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 481
---
 that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital and accumulated deficit.

<div align='center'>F-42</div>

TABLE OF CONTENTS

IRIS ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS As of December 31, 2023 and 2022, the common stock reflected on the balance sheets are reconciled in the following table:

| ​ | Class A common stock subject to possible redemption at January 1, 2022    | ​ | ​ | ​ | $ |  276,000,000 | ​ | ​ |
| ​ | Plus: Remeasurement of carrying value to redemption value                 | ​ | ​ | ​ | ​ |    3,091,534 | ​ | ​ |
| ​ | Less: Shares redeemed in December 2022                                    | ​ | ​ | ​ | ​ | -263,963,913 | ​ | ​ |
| ​ | Class A common stock subject to possible redemption at December 31, 2022  | ​ | ​ | ​ | ​ |   15,127,621 | ​ | ​ |
| ​ | Less: Remeasurement of carrying value to redemption value                 | ​ | ​ | ​ | ​ |     -420,786 | ​ | ​ |
| ​ | Less: 2023 adjustment to share price for shares redeemed in December 2022 | ​ | ​ | ​ | ​ |     -298,431 | ​ | ​ |
| ​ | Less: Shares redeemed in September 2023                                   | ​ | ​ | ​ | ​ |  -10,358,754 | ​ | ​ |
| ​ | Class A common stock subject to possible redemption at December 31, 2023  | ​ | ​ | ​ | $ |    4,049,650 | ​ | ​ |

Warrants — Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment as discussed herein.